Markets:

Overview

News

Currencies

International

Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

43.50 -0.45 (-1.02%)

Streaming Delayed Price Updated: 2:14 PM EST, Feb 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2

...

15 16 17 18 19 20 21 22 Next >

Nasdaq Bear Market: 3 Surefire Growth Stocks to Buy to End the Year Right ↗

November 30, 2022

Investors can end the year on a high note by scooping up shares of these bargain-basement-priced growth stocks.

Via The Motley Fool

The Smartest Stocks to Buy With $20 Right Now ↗

November 16, 2022

You don't need a mountain of cash to begin building wealth on Wall Street.

Via The Motley Fool

2 No-Brainer Stocks to Buy Right Now for Less than $20 ↗

November 12, 2022

These stocks are still bargain-priced but benefit from long-term trends.

Via The Motley Fool

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November

November 10, 2022

From Exelixis, Inc.

Via Business Wire

Here's Why This Growth Stock Is Already My 2022 Winner ↗

November 09, 2022

Despite a challenging year for the markets, this growth stock managed to stand out with another stellar quarter.

Via The Motley Fool

What 4 Analyst Ratings Have To Say About Exelixis ↗

November 02, 2022

Exelixis (NASDAQ:EXEL) has observed the following analyst ratings within the last quarter:

Via Benzinga

Exelixis Inks Two Licensing Pacts For Cancer Programs ↗

November 02, 2022

Via Benzinga

Exelixis (EXEL) Q3 2022 Earnings Call Transcript ↗

November 02, 2022

EXEL earnings call for the period ending September 30, 2022.

Via The Motley Fool

Looking Into Exelixis's Return On Invested Capital ↗

November 08, 2022

Pulled from Benzinga Pro data, Exelixis (NASDAQ:EXEL) posted Q3 earnings of $73.21 million, an increase from Q2 of 3.59%. Sales dropped to $411.74 million, a 1.83% decrease between quarters.

Via Benzinga

Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis’ Biologics Pipeline

November 03, 2022

From Exelixis, Inc.

Via Business Wire

Exelixis and Sairopa Establish Exclusive Clinical Development Collaboration and Option Agreement to Develop ADU-1805, a Potentially Best-in-Class Monoclonal Antibody Targeting SIRPα

November 01, 2022

From Exelixis, Inc.

Via Business Wire

Exelixis Announces Detailed Results From Late-Stage Cabometyx Combo Trial In Kidney Cancer ↗

September 08, 2022

Via Benzinga

Exelixis and Cybrexa Therapeutics Establish Exclusive Collaboration Providing Exelixis the Right to Acquire CBX-12, a Potential First-in-Class Peptide-Drug Conjugate of Exatecan

November 01, 2022

From Exelixis, Inc.

Via Business Wire

Exelixis Announces Third Quarter 2022 Financial Results and Provides Corporate Update

November 01, 2022

From Exelixis, Inc.

Via Business Wire

Nasdaq Bear Market: 5 Magnificent Growth Stocks You'll Regret Not Buying on the Dip ↗

October 29, 2022

With the Nasdaq Composite down as much as 38% from its peak, these highly innovative companies are ripe for the picking.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022 ↗

November 01, 2022

Upgrades

Via Benzinga

2 Top Biotech Stocks to Buy for the Long Haul ↗

October 28, 2022

Both drugmakers have outperformed the market in the past year.

Via The Motley Fool

Exelixis Announces Promising Initial Dose-Escalation Results from the First-in-Human Phase 1 JEWEL-101 Trial Evaluating XB002 in Patients with Advanced Solid Tumors at ENA 2022

October 26, 2022

From Exelixis, Inc.

Via Business Wire

Worried About Rising Interest Rates? These 2 Growth Stocks Could Offer a Solution ↗

October 19, 2022

These stocks have low-to-no debt, and analysts see tons of upside.

Via The Motley Fool

Exelixis to Release Third Quarter 2022 Financial Results on Tuesday, November 1, 2022

October 18, 2022

From Exelixis, Inc.

Via Business Wire

The Smartest Stocks to Buy With $20 Right Now ↗

October 14, 2022

Cheap stocks have the ability to generate enormous, long-term profits for investors.

Via The Motley Fool

These 7 Biotech Stocks Are Set to Boom in 2023 ↗

October 10, 2022

This article looks at seven biotech stocks that look like good options to move significantly higher in 2023

Via InvestorPlace

Exelixis Expands Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Include the Fixed-Dose Combination of Nivolumab and Relatlimab in Combination with XL092 in Phase 1b STELLAR-002 Trial

October 04, 2022

From Exelixis, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2022 ↗

October 18, 2022

Upgrades

Via Benzinga

3 Biotech Stocks to Buy Now for Extraordinary Gains ↗

September 20, 2022

These biotech stocks should deliver big gains to long-term investors who purchase shares at a discount during the bear market.

Via InvestorPlace

Exelixis' XL092/ Atezolizumab Shows Encouraging Efficacy, Safety In Heavily Pretreated Cancer Patients ↗

September 12, 2022

Via Benzinga

Exelixis Announces Dose-Escalation Results from the Phase 1 STELLAR-001 Trial Evaluating XL092 Alone and in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ESMO 2022

September 10, 2022

From Exelixis, Inc.

Via Business Wire

Exelixis Announces Detailed Results from Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer at ESMO 2022

September 07, 2022

From Exelixis, Inc.

Via Business Wire

Exelixis To Webcast Fireside Chats as Part of Investor Conferences in September

September 06, 2022

From Exelixis, Inc.

Via Business Wire

Stock Market Rally Rises On Inflation Data; Nvidia, Micron, Tesla, Disney In Focus: Weekly Review ↗

August 12, 2022

The major indexes continued to advance, despite some key warnings.

Via Investor's Business Daily

< Previous 1 2

...

15 16 17 18 19 20 21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.